Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers Authors: Kole H. Buckley, Yuhan Zhu, Kevin Dinh, Ryan Hausler, Rohan Gala, Sophia R. Spiegel, Rosella Delgado, Daniel G. Clay, Gregory M. Kelly, Jamie Brower, Susan M. Domchek, Kara N. Maxwell, Bryson W. Katona Published: 2026 ABSTRACT ABSTRACTRecent evidence suggests that carriers of a pathogenic germline variant (PGV) in BRCA1 or BRCA2 may have an increased risk of gastric cancer (GC). However, the specific mechanisms underlying gastric carcinogenesis remain uncertain. Strikingly, recent data have demonstrated that Japanese BRCA1 and BRCA2 PGV carriers with Helicobacter pylori (Hp) exposure have a substantially increased risk of GC compared to non‐carriers with Hp exposure, indicating that Hp may be an important risk factor for BRCA1 and BRCA2‐associated GC. However, rates of Hp exposure amongst broader BRCA1 and BRCA2 PGV cohorts are currently unknown. In this study, 1034 United States‐based BRCA1 and BRCA2 PGV carriers along with 293 PALB2, ATM, and TP53 PGV carriers were assessed for Hp exposure by assessing Hp IgG positivity in plasma samples. The combined rate of Hp exposure in BRCA1 and BRCA2 carriers was 17.4%. Individually, BRCA1 and BRCA2 carriers had an exposure rate of 16.4% and 18.2%, respectively. Similarly, PALB2, ATM, and TP53 carriers had a combined Hp exposure rate of 18.4%. Among all groups, non‐White race was significantly associated with Hp exposure. Approximately 1 in 6 BRCA1, BRCA2, and other DNA repair‐related gene PGV carriers had Hp exposure. Future studies are needed to determine the impact of Hp exposure versus active Hp infection on GC risk in these high‐risk individuals. Abbreviations enzyme‐linked immunosorbent assay gastric cancer Helicobacter pylori pathogenic germline variant Introduction Carriers of a pathogenic germline variant (PGV) in BRCA1 and BRCA2 have a well‐established increased risk of multiple cancers, including breast, ovarian, pancreatic, and prostate cancers [1, 2]. Additionally, an accumulating body of evidence suggests BRCA2, and to a slightly lesser extent, BRCA1 PGV carriers may also have an increased risk of gastric cancer (GC) [3], with more recent data from the past 2 years affirming this trend in both BRCA1 and BRCA2 carriers in different study populations [4, 5, 6, 7, 8]. Furthermore, normal gastric epithelium of United States‐based BRCA1 and BRCA2 PGV carriers has been shown to harbor augmented growth and increased DNA damage, thus illustrating a potential early event that may contribute to gastric carcinogenesis in BRCA1/2 carriers [9]. Importantly, a recent study showed that BRCA1 and BRCA2 PGV carriers with Helicobacter pylori (Hp) exposure have up to a nine‐fold higher cumulative risk of GC at age 85 compared to carriers without detectable Hp exposure [10]. This finding was consistent among other DNA repair‐related gene (e.g., ATM and PALB2) PGV carriers [10], and suggests that BRCA1 and BRCA2 PGV carriers along with PGV carriers of other DNA repair‐related genes may be particularly susceptible to Hp‐induced GC. However, at this time, guidelines do not recommend Hp assessment nor regular gastric screening for most of these carriers. Hp is a well‐described GC risk factor amongst the general population, with infected individuals having up to a six‐fold increased risk of GC [10]. While nearly half of the world's population carries an active Hp infection, a recent report estimates that approximately 1 in 6 (18%) individuals in the United States is infected [11]. Previously, our group showed that only 1% of a United States‐based cohort of BRCA1 and BRCA2 carriers displayed an active Hp infection through histologic examination of non‐targeted gastric biopsies obtained during an upper endoscopy [12]. However, histologic examination of gastric biopsy tissue can be prone to sampling error and does not allow determination of whether an individual had prior Hp exposure. Furthermore, this previously reported cohort was small (100 combined BRCA1 and BRCA2 carriers) and primarily composed of older individuals [12]. In this current study, we aimed to expand upon these initial findings by assessing Hp exposure in a large cohort of BRCA1 and BRCA2 PGV carriers. Additionally, we aimed to identify potential risk factors for Hp exposure and compare these results to Hp exposure rates from PGV carriers of other DNA repair‐related genes (i.e., ATM, PALB2, and TP53). To evaluate prior Hp exposure we analyzed carrier plasma samples for Hp IgG positivity. Importantly, Hp IgG can be detected for years post clearance or after eradication of Hp [13, 14, 15]. Therefore, Hp IgG positivity represents both prior and active Hp infection, allowing a broader assessment of which individuals have had Hp exposure compared to assessing for active Hp infection alone. By identifying Hp exposure rates and potential risk factors among BRCA1, BRCA2, and other PGV carriers, we then aimed to identify specific subgroups of carriers that may be particularly at risk of Hp exposure, which may help inform future GC risk reduction strategies for BRCA1 and BRCA2 PGV carriers. Methods Study Cohort and Selection Criteria Carriers were selected for this study if they carried a PGV in BRCA1, BRCA2, ATM, PALB2, or TP53 and had a banked plasma sample that could be used for research. Amongst carriers that met this criteria, there was no further exclusion based on cancer history or any other demographic characteristic. While GC was not an exclusion criteria for this study, none of the carriers assayed had a personal history of GC at the time of sample collection. Plasma samples were obtained from 1327 distinct high‐risk individuals including 456 BRCA1, 578 BRCA2, 27 ATM, 55 PALB2, and 211 TP53 PGV carriers. These samples were collected across multiple IRB‐approved studies at the University of Pennsylvania including the Cancer Risk Evaluation Program Biobank (IRB# 816688), Clinical and Molecular Studies of Li‐Fraumeni Syndrome and TP53‐associated Disorders (IRB# 834147), PRECEDE study (NCT02000089, IRB# 843215), and the CAPS5 study (NCT04970056, IRB# 819110). After collection, all plasma samples were stored at −80°C until the time of analysis. Clinical and Demographic Data Acquisition All clinical and demographic data were acquired through data abstraction from the electronic medical record at Penn Medicine by study team members. Hp IgG Detection A commercially available Hp IgG detection enzyme‐linked immunosorbent assay (ELISA) kit (Abcam; AB178645) was used to detect Hp IgG seropositivity. This kit has been previously validated in our laboratory [16]. Samples were tested in triplicate according to the manufacturer's instructions. Briefly, plasma samples from each carrier were diluted 1:100 with IgG Sample Diluent, along with both positive and negative controls. 100 μL of each diluted sample and controls were dispensed into individual wells of a 96 well Hp coated microplate and incubated for 1 h at 37°C. Each well was then washed three times with 300 μL of 1× Washing Solution. 100 μL of HRP conjugate was then added to each well and incubated for 30 min at room temperature, protected from light. The wells were again washed three times with 300 μL of 1× Washing Solution followed by 100 μL of TMB Substrate Solution and allowed to incubate for 30 min at room temperature, protected from light. The reaction was terminated by adding 100 μL of Stop Solution to each well and absorbance was measured at 450 nm along with a reference wavelength at 620 nm using a microplate reader (Molecular Devices; SpectraMax M2). Mean absorbance readings were plotted on a standard curve to calculate Hp IgG concentration in IU/mL. Samples were defined as positive at > 20 IU/mL and negative at < 15 IU/mL. Samples with Hp IgG concentrations between 15 and 20 IU/mL were considered equivocal and retested. If Hp IgG concentrations remained equivocal upon retesting, the sample was considered negative. Statistics Statistical associations between Hp IgG status and cohort characteristics were determined via Fisher's exact test. p values were adjusted for multiple comparisons using the Bonferroni correction. Results Hp Exposure Rates and Risk Factors Amongst BRCA1 and BRCA2 PGV Carriers A combined total of 1034 BRCA1 and BRCA2 PGV carrier plasma samples were tested for Hp IgG, of which 180 (17.4%) were seropositive (Figure 1). Individually, 75 (16.4%) of the BRCA1 samples tested positive for Hp IgG and 105 (18.2%) of the BRCA2 samples tested positive. Hp exposure rates amongst BRCA1, BRCA2, PALB2, ATM, and TP53 PGV carriers. Hp IgG positivity was assessed in all 1327 BRCA1, BRCA2, PALB2, ATM, and TP53 PGV carriers. This included 1034 BRCA1 and BRCA2 PGV carriers combined (456 BRCA1 carriers, 578 BRCA2 carriers), and 293 PALB2, ATM, and TP53 PGV carriers combined. To identify groups of BRCA1 and BRCA2 PGV carriers who may have increased likelihood of Hp exposure, clinical and demographic data were ascertained (Table 1), demonstrating that increasing age and non‐White race were statistically significantly associated with Hp IgG positivity, while germline variant (BRCA1 vs. BRCA2), Ashkenazi Jewish ancestry, alcohol use, smoking, marital status, and a family history of GC were not. TABLE 1 BRCA1 and BRCA2 PGV carrier characteristics associated with H. pylori exposure.Characteristic H. pylori IgG positive H. pylori IgG negative p Adjusted p Age (years), mean (SD)56.9 (14.8)53.1 (14.4)0.00210.017SexMale, n (%)22 (18.5)97 (81.5)0.801Female, n (%)159 (17.3)758 (82.7)Pathogenic germline variant BRCA1, n (%)75 (16.4)381 (83.6)0.461 BRCA2, n (%)106 (18.3)474 (81.7)RaceWhite, n (%)149 (15.9)786 (84.1)0.00002120.000191Other, n (%)32 (35.2)59 (64.8)Ashkenazi Jewish ethnicityAshkenazi Jewish, n (%)53 (14.5)313 (85.5)0.050.38Non‐Ashkenazi Jewish, n (%)114 (19.5)472 (80.5)AlcoholAlcohol ever, n (%)99 (16.2)512 (83.8)0.080.49Alcohol never, n (%)23 (26.4)64 (73.6)SmokingHas smoked, n (%)45 (18.6)197 (81.4)0.611Never smoked, n (%)86 (16.9)423 (83.1)Marital statusMarried, n (%)115 (17.9)525 (82.1)0.561Not married, n (%)47 (16.2)243 (83.8)Family history of gastric cancerYes, n (%)14 (20.0)56 (80.0)0.631No, n (%)167 (17.4)793 (82.6) BRCA1 and BRCA2 PGV carrier characteristics associated with H. pylori exposure. Hp Exposure Rates and Risk Factors Amongst PALB2 , ATM , and TP53 PGV Carriers To determine if Hp exposure rates were similar in other DNA repair‐related genes, 293 combined PALB2, ATM, and TP53 PGV carrier plasma samples were tested for Hp IgG positivity (Figure 1). 54 (18.4%) were seropositive for Hp IgG, which is a similar rate compared to the cohort of BRCA1 and BRCA2 PGV carriers. When evaluating for potential associations with Hp exposure, only non‐White race was statistically significantly associated with Hp IgG seropositivity among PALB2, ATM, and TP53 PGV carriers (Table 2). TABLE 2 ATM, PALB2, and TP53 PGV carrier characteristics associated with H. pylori exposure.Characteristic H. pylori IgG positive H. pylori IgG negative p Adjusted p Age (years), mean (SD)48 (18.1)43.4 (20.1)0.110.66SexMale, n (%)36 (17.3)172 (82.7)0.731Female, n (%)16 (19.5)66 (80.5)RaceWhite, n (%)27 (13.0)180 (87.0)0.001230.00984Other, n (%)25 (29.7)59 (70.3)Ashkenazi Jewish ethnicityAshkenazi Jewish, n (%)7 (19.4)29 (80.6)0.820.38Non‐Ashkenazi Jewish, n (%)38 (18.3)170 (81.7)AlcoholAlcohol ever, n (%)36 (19.0)153 (81.0)0.390.49Alcohol never, n (%)6 (27.3)16 (72.7)SmokingHas smoked, n (%)12 (17.4)57 (82.6)11Never smoked, n (%)33 (18.4)146 (81.6)Marital statusMarried, n (%)29 (18.5)127 (81.5)0.621Not married, n (%)16 (15.8)85 (84.2)Family history of gastric cancerYes, n (%)4 (20.0)16 (80.0)0.771No, n (%)46 (18.6)201 (81.4) ATM, PALB2, and TP53 PGV carrier characteristics associated with H. pylori exposure. Discussion In this study, we show that amongst a large United States‐based cohort of BRCA1 and BRCA2 PGV carriers, the Hp exposure rate was 17.4%. The rate of Hp exposure was similar amongst a cohort of United States‐based PALB2, ATM, and TP53 PGV carriers as well (18.4%). These rates are also similar to other United States‐based cohorts of individuals with hereditary GC risk, including Lynch syndrome (14%) [16]. The Hp exposure rates, which include both prior and active infection, were also similar to a recent report of active Hp infection amongst the general United States population (18%) [11], suggesting that United States‐based BRCA1 and BRCA2 PGV carriers (among other DNA repair‐related PGV carriers) do not have an increased risk of Hp infection nor Hp exposure. Hp exposed BRCA1 and BRCA2 PGV carriers from Japan show evidence of a synergistic increase in GC risk compared to Hp exposed individuals from Japan with no documented PGVs [10], however it remains unknown whether similar associations are observed in Western BRCA1 and BRCA2 PGV cohorts. Furthermore, while Hp eradication in both symptomatic and asymptomatic individuals in the general population has been well documented to decrease GC risk [17, 18, 19], it also remains unknown whether prior Hp exposure and subsequent eradication in BRCA1 and BRCA2 PGV carriers can similarly reduce lifetime risk of GC. Determining whether active Hp infection and/or Hp exposure alone have an impact on GC risk for BRCA1 and BRCA2 PGV carriers will likely have important implications regarding whether Hp assessment and/or surveillance is recommended for this cohort. However, in our opinion, baseline testing for active Hp (e.g., gastric biopsy, urea breath test, stool antigen) can be considered for all BRCA1 and BRCA2 PGV carriers at the time of genetic diagnosis, with eradication therapy provided to those who test positive for active infection. When assessing risk factors for Hp exposure, we found that for BRCA1 and BRCA2, as well as PALB2, ATM, and TP53 PGV carrier cohorts, non‐White race was statistically significantly associated with Hp exposure. Non‐White race has previously been established as a risk factor for Hp infection amongst the global population [20, 21, 22]. While our study did not risk stratify by socioeconomic status, a recent investigation showed Hp exposure rates of over 40% amongst United States‐based individuals with lower socioeconomic status, regardless of race or ethnicity [23]. Taken together, these findings suggest non‐White race and socioeconomic status may be important risk factors when considering Hp screening in United States‐based BRCA1 and BRCA2 PGV carriers, as well as PALB2, ATM, and TP53 PGV carriers. Limitations to this study include that the population was primarily White, female, and from a single center in the United States. While Hp IgG tests for Hp exposure, it is unable to determine whether or not an individual has an active Hp infection. Additionally, the ELISA assay used in this study is unable to distinguish between different Hp strains and virulence. The most common Hp strains in the United States consist of the Type I motif [24, 25]. In conclusion, nearly 1 in 6 United States‐based BRCA1 and BRCA2 PGV carriers (among other DNA repair‐related PGV carriers) have detectable Hp exposure, which is higher than previously published active rates of Hp in these carriers [12]. However, whether prior Hp exposure alone, in the absence of active Hp infection, has a role in increasing GC risk in BRCA1 and BRCA2 PGV carriers remains uncertain. Therefore, at this time, testing for active Hp infection can be considered in all BRCA1 and BRCA2 PGV carriers at the time of genetic diagnosis. Future studies focused on the role of Hp exposure versus active infection in BRCA1 and BRCA2 PGV carriers to better determine their impacts on GC risk will be crucial for informing future GC risk management strategies for these high‐risk individuals. Author Contributions Kole H. Buckley: conceptualization, investigation, writing – original draft, methodology, validation, visualization, writing – review and editing, software, formal analysis, data curation, supervision. Yuhan Zhu: methodology, validation, writing – review and editing, formal analysis, data curation. Kevin Dinh: methodology, validation, writing – review and editing, formal analysis, data curation. Ryan Hausler: writing – review and editing, methodology, validation, software, formal analysis, data curation, resources. Rohan Gala: methodology, validation, writing – review and editing, formal analysis, data curation. Sophia R. Spiegel: writing – review and editing, methodology, resources, data curation, software. Rosella Delgado: methodology, writing – review and editing, software, data curation, resources. Daniel G. Clay: writing – review and editing, resources. Gregory M. Kelly: writing – review and editing, resources. Jamie Brower: writing – review and editing, resources. Susan M. Domchek: writing – review and editing, resources. Kara N. Maxwell: writing – review and editing, resources. Bryson W. Katona: conceptualization, investigation, funding acquisition, writing – original draft, methodology, validation, visualization, writing – review and editing, resources, supervision, data curation, project administration, formal analysis, software. Funding This work was supported by University of Pennsylvania Genomic Medicine T32, HG009495; Basser Center for BRCA and the Basser Center Men & BRCA program. Ethics Statement This study was approved by the University of Pennsylvania institutional review board (IRB#s 816688, 834147, 843215, 819110). Informed consent was provided by all participants. Conflicts of Interest The authors declare no conflicts of interest.